Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Abivax S.A.NASDAQ: ABVX

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables grows 864.7% year over year

Q2 FY2026 accounts payables of €9.49M rose 864.7% year over year.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€9.49M— QoQ
Last fiscal yearDec 2025
€0+100.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+864.7%——
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
+100.0%

Accounts Payables vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.0% is the 4th highest of 10, against a peer median of +38.3%.
ABVX Competitors
Accounts Payables for ABVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$81.11M USD+53.9%—34.9%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M USD+537.3%—3.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$8.3M USD+286.2%+184.2%99.2%
ANNXAnnexon, Inc.LTM Mar 2026$6.67M USD+3.7%——
RCUSArcus Biosciences, Inc.LTM Jun 2026$5M USD-66.7%+44.2%4.3%
IVAInventiva S.A.FY2025€2.46M EUR—-11.4%54.8%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$1.46M USD+112.4%—1.6%
IMMXImmix Biopharma, Inc.LTM Mar 2026$1.2M USD-56.1%-3.2%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$796K USD-35.7%—0.4%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$325K USD+38.3%-33.1%550.8%
ABVXAbivax S.A.FY2025€0 EUR+100.0%——
Peer median (excluding ABVX) —+38.3%-3.2%19.6%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(322.84M)
Depreciation & Amortization302K485K707K1.1M1.07M
Deferred Income Tax007.93M00
Stock-Based Compensation828K(1.16M)8.18M20.22M0
Change in Working Capital(668K)(2M)21.27M1.42M3.51M
Accounts Receivables(1.98M)312K(14.23M)4.59M6.76M
Inventory00000
Accounts Payables1.14M(2.39M)31.76M(3.44M)0
Other Working Capital168K74K3.74M276K(3.26M)
Other Non-Cash Items(3.06M)9.49M9.65M(577K)162.57M
Operating Cash Flow(45.05M)(53.94M)(100.01M)(154.07M)(155.69M)
Capital Expenditures(47K)(323K)(265K)(643K)(136.4K)
Acquisitions (Net)(2.18M)(2.91M)000
Purchases of Investments(9K)(470K)(9.35M)0(13.59M)
Sales of Investments0218K741K0480.27K
Other Investing Activities(4M)(8.57M)(1.62M)16.4M68.2K
Investing Cash Flow(6.23M)(12.03M)(10.5M)15.76M(13.18M)
Debt Repayment19.13M(9.71M)15.24M37.49M(56.31M)
Common Stock Issued69.68M46.37M353.39M434K588.84M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(6.13M)(4.45M)(28.06M)(9.71M)(586.89K)
Financing Cash Flow82.68M32.21M340.57M28.21M531.94M
Effect of Forex Changes00(5.07M)2.38M26.29M
Net Change in Cash31.4M(33.75M)224.99M(107.72M)389.36M
Free Cash Flow(45.1M)(54.26M)(100.28M)(154.72M)(155.83M)

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.